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Background: Sarcoidosis is a granulomatous disease affecting in particular the lungs. The peroxisome
proliferator-activated receptors (PPARs) play important regulatory roles in inflammation. The aim of this study was
to gain more insight about the expression of all three PPARs (α, β/δ and γ) in sarcoidosis.
Methods: Bronchoalveolar lavage (BAL) cells and peripheral blood cells were obtained from healthy controls (HC)
and sarcoidosis patients with Löfgren’s syndrome (LS) and without Löfgren’s syndrome (non-LS). PPARs mRNA
expression was analyzed in total BAL cells and in FACS (Fluorescence-activated cell sorting) sorted alveolar
macrophages (AM) and CD4+ T cells respectively by comparative RT-PCR. PPARs protein expression was analyzed
in AM, and in BAL and blood CD4+ and CD8+ T cells by flow cytometry.
Results: In BAL CD4+ T cells, we noticed a significantly lower PPARα mRNA expression in sarcoidosis patients
compared with HC. In non-LS patients, a significantly lower PPARα protein expression in BAL CD4+ T cells was
detected as compared with LS patients. In peripheral blood CD4+ T cells, non-LS patients had a significantly lower
expression of PPARα and PPARγ compared with LS patients.
Conclusion: The lower protein expression of PPARα and PPARγ could contribute to the persistent T-cell driven
inflammation noted especially in non-resolving sarcoidosis, common in non-LS patients.
Keywords: Peroxisome proliferator-activated receptors α, β/δ and γ, Sarcoidosis, Bronchoalveolar lavage (BAL),
Flow cytometry, BAL and blood CD4+- and CD8+ T lymphocytes, Alveolar macrophages, RT-PCRIntroduction
Sarcoidosis is a systemic disease characterized by nonca-
seating granulomas affecting many organs, in particular
the lungs and the intrathoracic lymph nodes [1]. Sar-
coidosis is a multifactorial [2] disease, where environ-
mental factors and several genetic loci contribute to the
pathogenesis of the disease [3]. Moreover, some studies
have suggested that sarcoidosis is associated with in-
creased risk of cancer [4,5]. The cause of sarcoidosis re-
mains elusive. Evidence points towards that sarcoidosis
is an exaggerated immune response to persistent anti-
gens from not completely degraded bacteria such as
mycobacteria and propionibacterium acnes [1].* Correspondence: muntasir.abo.al.hayja@ki.se
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unless otherwise stated.In sarcoidosis, the interaction between antigen presenting
cells (APCs) and an unknown antigen(s) leads to a polar-
ized T-helper 1 (Th1) CD4+ response including production
of Th1 cytokines such as interferon-gamma (IFN-γ), tumor
necrosis factor-α (TNF-α) and interleukin-2 (IL-2) [1], and
the formation of granulomas. Pulmonary sarcoidosis is
characterized by an increased number of CD4+ T cells in
bronchoalveolar lavage fluid (BALF). Analyses of the T Cell
Receptor (TCR) suggest oligoclonal expansion of the CD4+
T cells using particular Vα or Vβ genes [3]. In most cases
the granulomas resolve, but in some cases the local envir-
onment of the granulomas may change to promote the de-
velopment of fibrosis [1].
The clinical presentation of sarcoidosis ranges from an
incidental chest radiographic finding in an asymptomatic
patient to chronic progressive organ dysfunction. A distinct
subgroup of sarcoidosis patients is Löfgren’s syndromeentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lymphadenopathy and in some cases parenchymal infil-
trates, erythema nodosum and/or bilateral ankle arthritis
or periarticular inflammation, and usually fever [3]. Patients
with LS often have spontaneously resolving disease, while
patients without LS (non-LS) often present with a more
gradual, insidious onset, and are more likely to develop
chronic disease. Studies from our laboratory of Swedish pa-
tients with sarcoidosis demonstrated a strong correlation
between the carriage of HLA-DRB1*0301 (DR3+) and the
development of LS and with disease resolution [3].
The peroxisome proliferator-activated receptors (PPARs)
play important regulatory roles in numerous cellular pro-
cesses related to metabolism, differentiation, proliferation,
and inflammation. PPARs are a subgroup of the nuclear
receptor (NR) superfamily. Three PPARs have been
described, which are designated as α, β/δ and γ forms.
The PPARs are expressed in many cell types, including
macrophages and T lymphocytes [6,7]. All three PPARs
subtypes can be activated by a variety of polyunsatur-
ated long-chain fatty acids, prostaglandins, leuko-
trienes, and by many synthetic compounds [8]. PPARα
is specifically activated by fibrates (used to treat hyper-
triglyceridemia and hyperlipidemia), whereas PPARγ is
activated by glitazones (used to treat diabetes type II).
PPARs regulate gene expression after binding as a
heterodimer with the retinoid X receptors (RXRs) and
accumulation in the nucleus. A major role for PPARs is
the trans-suppression of inflammatory gene activation
by interfering with the NF-κB, STAT-1, and AP-1 tran-
scription complexes without direct binding to the DNA
[9]. PPARα PPARβ/δ and PPARγ ligands have been re-
ported to inhibit Th1 pro-inflammatory cytokine pro-
duction by activated T cells [10,11].
PPARα and PPARγ are recognized as potentially import-
ant players in immunomodulation and anti-inflammatory
regulation in different inflammatory disorders including
pulmonary diseases such as COPD and asthma [6]. To
date, the expression and function of PPARs in pulmonary
sarcoidosis is scantily documented. Alveolar macrophages
(AM) from patients with active chronic sarcoidosis ex-
hibited a deficiency of PPARγ activity, and PPARγ gene
expression in BAL cells was reduced in patients with
severe disease [12,13]. To our knowledge, the expres-
sion of PPARα and PPARβ/δ in sarcoidosis has not
been documented.
Considering the regulatory and immunomodulatory
actions of PPARs, we hypothesized that down regulation
of their expression in sarcoidosis may represent a mech-
anism leading to the promotion of inflammation. The
aim of this study was to gain more insight about the ex-
pression of all three PPARs (α, β/δ and γ) in human AM
and CD4+ T cells in LS and non-LS patients in compari-
son to healthy controls (HC).Methods
Study subjects
All included patients in this study were referred to the
Lung and Allergy clinic (at Karolinska University Hospital
or at Stockholm South General Hospital, Stockholm,
Sweden) for an investigational work up of clinically sus-
pected pulmonary sarcoidosis. The diagnosis of sarcoidosis
in the non-Löfgren patients was established by clinicora-
diographic findings compatible with the disease and in
most cases by biopsies showing non-caseating epithelioid
granuloma. If biopsies were negative despite typical clini-
coradiographic findings the diagnosis was considered
likely if BALF analysis showed a CD4+/CD8+ ratio > 4 and
the diagnosis remained the same at follow-ups. In
addition, other causes of sarcoid like diseases and reac-
tions were reasonably excluded [14,15]. In Löfgren pa-
tients the diagnosis of presumptive sarcoidosis was made
with high confidence based on typical clinical findings,
provided there are no other explanations for the symptoms.
Furthermore, the patients had BALF with a high percentage
of lymphocytes and a CD4+/CD8+ ratio > 4 [16]. Written
informed consent was obtained from all subjects, and the
Regional Ethical Review Board (Stockholm, Sweden) ap-
proved the study.
A total of 29 healthy controls (HC) and 57 sarcoidosis
patients were sequentially recruited to this study (clinical
and BAL cells characteristics are summarized in Table 1).
All HC were non-smokers, had normal lung function re-
sults, unremarkable chest X-ray, and none of them
showed any signs of lower respiratory tract infection at
least six weeks prior to the bronchoscopy. All patients
had a clinical picture completely consistent with sarcoid-
osis, and they were subdivided into two groups accord-
ing to their clinical phenotypes: Löfgren’s syndrome (LS)
and non-LS. Patients were also classified as being HLA
allele DRB1*0301 (DR3) positive or DR3 negative.
Twenty-seven patients had LS, (74% DR3+, median age
39 years (min-max: 28–56, 15 females and 12 males)).
Thirty patients had non-LS (80% DR3−, median age 47
(min-max: 27–71, 9 females and 21 males)). Only pa-
tients, who did not receive anti-inflammatory or im-
munosuppressive medications, were included into the
study. None of the patients included in this study was
on treatment with fibrates or glitazones.
The study progressed through three sequential stages. In
the first stage, the expression of PPARs mRNA in total
BAL cells was analyzed in 6 HC and 16 sarcoidosis (7 LS
and 9 non-LS) patients. In the second phase, the expres-
sion of PPARs mRNA in FACS (Fluorescence-activated
cell sorting) sorted BAL CD4+ T lymphocytes and AM
were analyzed separately in a total 19 HC and 34 sarcoid-
osis (17 LS and 17 non-LS) patients. In the last stage,
PPARs protein expression in BAL and blood CD4+- and
CD8+ T lymphocytes and AM was investigated by using
Table 1 Characterization of sarcoidosis patients and HC
Löfgren’s Non-Löfgren’s Healthy controls
Subjects number 27 30 29
Age 39 (28–56)**** 47 (27–71)**** 26 (18–42) ¤
Sex, female/male 15/12 9/21 15/14
smoking history (NS/FS/OS/CS) 20/5/2/0 16/13/1/0 29/0/0/0
Radiograph stages (0,I, II, III, IV, ND) 0/16/9/0/0/2 0/7/9/4/4/6 29/0/0/0/0
HLA (DR3+/DR3-/ND) 20/6/1 3/24/3 ND
BAL analysis
Recovery % 68 (44–80) 63,5 (44–84) 72 (34–88)
Viability % 95 (85–99) 95 (78–98) 95 (88–98)
Cell concentration (*106/L) 225 (49–588)**** 188 (83,5-476)**** 90,5 (29–167) ¤
Total cell number (*106) 36 (9–77)**** 28 (10–81)*** 16 (5–31,5) ¤
BAL differential cell counts
% Macrophages 68 (39,4-91)**** 71 (39,70-85)**** 87 (60,8-97,2) ¤
% Lymphocytes 30 (8,5-57,8)**** 26 (13–58,2)**** 11 (2,4-33,7) ¤
% Neutrophils 1,0 (0–5,8) 1,0 (0–6) 1,8 (0,2-6)
% Eosinophils 0,3 (0–2,5) 0,3 (0–4,4) 0,2 (0–1,6)
CD4/CD8 ratio 9,6 (1,1-28)**** 5,8 (1,6 -33)*** 2,65 (0,9-4,8) ¤
Pulmonary function tests
FVC (% of predicted value) 90 (67–120)**** 84 (50–105)**** 111 (86–130) ¤
FEV1 (% of predicted value) 87 (61–104)*** 82 (46–112)**** 107 (86–125) ¤
TLC (% of predicted value) 92 (82–123)** 85 (62–186) # ND
DLCO (% of predicted value) 86 (66–126) 82 (54–130) ND
Data are presented as median (minimum-maximum). NS: never smoker, FS: former smoker, OS: occasional smoker, CS: current smoker. Radiographic stages 0:
normal, stage I: bilateral hilar lymphadenopathy (BHL), stage II: BHL and parenchymal infiltrates, stage III: parenchymal infiltrates without BHL, stage IV: signs of
fibrosis. BAL: bronchoalveolar lavage; VC: vital capacity; FEV1: forced expiratory volume in 1 s; DLCO: diffusing capacity of the lung for carbon monoxide; ND: not
determined; ¤ Kruskal-Wallis test was used to compare all three groups and a significant difference was only observed when LS and non-LS patients were compared with
HC; # Mann–Whitney U-test between LS and non-LS patients; **: p < 0.01, ***: p < 0.001, ****: p < 0.0001.
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(4 LS and 5 NLS) were recruited for this flow cytometry
analysis. Due to limitations in numbers of BAL and blood
cells available for this study, some samples of patients and
HC could not be included in all types of analyses. How-
ever, to ensure no selection bias, all individuals were ran-
domly included in the different experiments. The exact
numbers of controls and patients in each group are indi-
cated in the figures.
Bronchoalveolar lavage (BAL) and preparation of cells
BAL was performed as previously described [17]. Briefly,
after light sedation and topical local anesthesia, a flexible
fiber-optic bronchoscope (Olympus Optical Co., Tokyo,
Japan) was passed trans-nasally and BAL was performed
in a subsegmental bronchus in the middle-lobe. BAL
was then performed by sequentially instilling and gently
suctioning 50 ml of warmed (37°C) and sterile phosphate-
buffered saline (PBS) solution five times. The BAL fluid
aliquots were pooled and collected in a siliconized plas-
tic vessel kept on ice at 4°C. The recovered volume aspercentage of total instilled fluid is indicated in Table 1.
The BALF was gently passed through a Dacron gauze
(Milipore, Cork, Ireland) and centrifuged at 400 g for
ten minutes at 4°C. The pellet was resuspended in PBS.
The cells were counted in a Bürker chamber. The ex-
pression of cell surface antigens (CD3, CD4, CD8) and the
CD4+ to CD8+ cell ratio were performed by flow cytomet-
ric analysis (BD FACSCanto II flow cytometer) using
monoclonal antibodies against CD3+ (Pacific Blue Mouse
Anti-human CD3, clone UCHT1; BD Biosciences),
CD4+ (APC-H7 Anti-human CD4, clone SK3; BD
Biosciences), CD8+ (AmCyan Anti-human CD8, clo-
neSK1; BD Biosciences) as previously described [18].
Flow cytometric sorting of BAL macrophages and
CD4+ T cells
BAL cells were stained with PE Mouse Anti-human
CD4, clone RPA-T4. The stained cells were sorted by
FACSVantage (BD Biosciences). BAL cells were gated on
lymphocytes and macrophages and the stained CD4+ T
cells and macrophages were effectively separated. The
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by flow cytometry, was approximately 98%.
Flow cytometric analysis of PPAR α, β/δ, γ
To detect intracellular PPAR α, β/δ, γ on a single cell
level in blood and BALF cells, flow cytometry was uti-
lized. The cells were fixed and permeabilized with the
BD Pharmingen™ Transcription Factor Buffer set (BD Bio-
sciences). The following primary antibodies and isotypes
controls were added: Mouse monoclonal [3B6/PPAR]
to PPAR alpha - ChIP Grade (ab2779), Mouse IgG2b
[PLPV219] - Isotype Control (ab91366), Mouse monoclo-
nal to PPAR delta (ab58137), Mouse IgG2a [ICIGG2A] -Figure 1 The relative mRNA expression in total BAL cells of (a) PPA
sarcoidosis (n = 16) and patients subgroups (LS = 7, non-LS = 9) are
the whiskers show minimum and maximum values. Each symbol representIsotype Control (ab91361), Mouse monoclonal [A3409A]
to PPAR gamma 1 + 2 - ChIP Grade (ab41928) and Mouse
IgG1 [ICIGG1] - Isotype Control (ab91353). The following
secondary antibody was used: Goat polyclonal Secondary
Antibody to Mouse IgG - H&L (DyLight® 488), pre-
adsorbed (ab96879) (Abcam). Cell surface staining with
anti- CD3, CD4, and CD8 was performed after block-
ade with mouse serum. Cells were analyzed on BD
FACSCanto II flow cytometer (BD Bioscience) and data
were processed using the web-based application Cyto-
bank [19] (Cytobank, Inc). Alveolar macrophages and
lymphocytes were gated based on characteristic light
scatter properties. Within the lymphocyte gate, aRα, (b) PPARβ/δ and (c) PPARγ of HC (n = 6), patients with
shown. The boxes show median (25th-75th percentiles) values and
s an individual patient.
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CD3+ gate, further gates were set on CD4+ and CD8+ cells
to identify CD3+CD4+ and CD3+CD8+ T cells respectively.
PPARs were then measured in CD4+ and CD8+ T cells and
macrophages. Quantitative levels of PPARs, expressed as
median fluorescence intensity (MFI), were determined after
subtraction of the background level calculated from sam-
ples labelled with isotype control antibodies.Figure 2 The relative mRNA expression FACS-sorted BAL CD4+ T cells
with sarcoidosis (n = 17) and patients subgroups (LS = 7, non-LS = 10)
and the whiskers show minimum and maximum values. Each symbol repreRNA extraction and cDNA synthesis
Depending on the cells count (≤5×105 or ≥ 106) total
RNA was isolated using the RNAqueous-micro kit or
the RNAqueous kit (Ambion®) according to the manu-
facturer’s instructions. The quantity of total RNA was
analysed using NanoDrop ND-1000Spectrophotometer
(NanoDrop Technologies, Wilmington, DE, USA). To
synthesize cDNA the high capacity RNA-to-cDNA kitof (a) PPARα, (b) PPARβ/δ and (c) PPARγ of HC (n = 12), patients
are shown. The boxes show median (25th-75th percentiles) values
sents an individual patient.
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instructions.
Analysis of PPAR α, β/δ, γ gene expression by real-time
PCR
Real-time quantitative PCR (RT-PCR) was performed
using gene-specific fluorogenic assays (TaqMan; Applied
Biosystems) and an ABI Prism 7700 Sequence Detection
System (Applied Biosystem). Proteasome Subunit, Beta
Type, 2 (PSMB2) was used as a reference gene to normalizeFigure 3 The relative mRNA expression in FACS-sorted BAL macrop
patients with sarcoidosis (n = 21) and patients subgroups (LS = 12, no
values and the whiskers show minimum and maximum values. Each symboRT-PCR in BAL cells in sarcoidosis [20]. For relative quan-
tification of PPARs gene expression in BAL cells, the
comparative Ct method was used according to the formula
2-ΔΔCt [21]. In the first step, the Ct of the target gene (PPAR
α, β/δ, γ) was normalized to the endogenous control
(PSMB2). In the second step, normalization to the median
value of PPAR (α, β/δ, γ) gene expression in a HC group
(calibrator sample) was performed. All samples were run in
duplicates to ensure the validity of the experiment. The fol-
lowing primers were used: PSMB2 (Hs01002946_m1),hages of (a) PPARα, (b) PPARβ/δ and (c) PPARγ of HC (n = 11),
n-LS = 9) are shown. The boxes show median (25th-75th percentiles)
l represents an individual patient.
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PPARγ (Hs00234592_m1) (Applied Biosystems).Statistical analysis
The nonparametric Mann–Whitney test or Kruskal-Wallis
test was used to compare the distributions (medians) of
two or three unmatched groups respectively. In the case of
Kruskal-Wallis test, the Dunn’s post test was used to com-
pare the difference between two groups. Wilcoxons signed
ranks test was used to calculate differences in PPARs ex-
pression in BAL and blood CD4+ T cells. Values of p < 0,05
(*) were regarded as significant. All statistical tests were
performed using the GraphPad PRISM version 6.04
(GraphPad Software, Inc).Results
PPARs mRNA expression in BAL fluid and blood cells
We first investigated PPARs mRNA expression levels in
total BAL cells in HC and sarcoidosis patients (Figure 1).
We found no significant differences in PPARα, PPARβ/δ
and PPARγ mRNA expression between sarcoidosis pa-
tients and HC. An increased expression of PPARβ/δ
mRNA was noted in non-LS patients compared with LS
patients and HC (Figure 1b).
We then investigated mRNA expression in FACS
sorted BAL CD4+ T cells (Figure 2). Here we noticed a
significantly lower PPARα mRNA expression in sarcoid-
osis patients compared with HC (Figure 2a). This reduc-
tion was noted in both LS patients and non-LS patients.
We also explored PPARs mRNA expression in FACS
sorted AM (Figure 3). We noticed no significant differ-
ences in PPARα, PPARδ and PPARγ expression between
sarcoidosis patients, including patient’s subgroups (LS
and non-LS) and HC.Figure 4 Representative histogram overlay (a) -in a patient with LS sy
plots on CD4+ T cells (b). Black histogram is the isotype control; light gra
fluorescence intensity of the isotype and PPARα on a logarithmic scale, and
medians using the x-axis channels are presented in the table.Flow cytometric analysis of PPARs protein expression in
blood and BAL cells
An illustrative histogram overlay of PPARα expression
in BAL CD4+ T cells in a patient with LS and the gating
hierarchy is shown in (Figure 4). A significantly lower
expression of PPARα in non-LS patients was detected
as compared with LS patients (Figure 5a). This was
observed also in the BAL CD8+ T subset (Additional
file 1: Figure S1 a).
In peripheral blood CD4+ T cells as well CD8+ T cells,
non-LS patients had a significantly lower expression of
PPARα as compared with LS patients (Figure 6a) and
(Additional file 2: Figure S2 a). In both CD4+ and CD8+
T cells of peripheral blood, a strong trend toward a
lower expression of PPARγ was also observed in non-LS
patients as compared with LS patients (Figure 6c) and
Additional file 2: Figure S2 c). This difference was statis-
tically significant (p < 0.05) when directly comparing LS
and non-LS patients.
A representative histogram overlay of PPARα expres-
sion in AM and the related FACS plot of BAL cells with
gating of AM is shown in (Figure 7). As shown in Figure 8,
we did not observe any significant difference in PPARs ex-
pression in AM of sarcoidosis patients from HC.
Comparison of PPARα, PPARβ/δ and PPARγ expression in
BAL and blood CD4+ T cells in the same individual
Comparison of MFI between PPARα, PPARβ/δ and
PPARγ expression in BAL and blood CD4+ T cells in the
same individual revealed a statistically significantly lower
expression of PPARβ/δ in blood CD4+ T cells as com-
pared with BAL CD4+ T cells of healthy individuals. The
same tendency was observed for PPARβ/δ expression in
LS and non-LS patients (Additional file 3: Figure S3 b);
the difference was statistically significant when allndrome- of PPARα expression in BAL CD4+ T cells and the gating
y histogram is the anti-PPARα. The x-axis of each histograms represents
the y-axis represents the total number of events. The values of the
Figure 5 Flow cytometric analysis of PPARs expression in BAL CD4+ T cells. (a) PPARα. (b) PPARβ/δ. (c) PPARγ. HC: (n = 6); LS patients
(n = 4); non-LS patients (n = 5). MFI: median fluorescence intensity. The boxes show median (25th-75th percentiles) values and the whiskers show
minimum and maximum values. Each symbol represents an individual patient.
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sions of PPARα, and PPARγ were comparable in BAL
and blood CD4+ T cells in the same individual in all
groups.
Discussion
Recognizing that PPARs have an important role in con-
trolling inflammatory responses [7], we investigated the
expression of PPARs in total BAL cells, in BAL AM and
in BAL and in peripheral blood CD4+ and CD8+ T cells
from healthy controls (HC) and from sarcoidosis pa-
tients with or without Löfgren’s syndrome (LS and
non-LS). Our data shows for the first time, that PPARα
expression is downregulated in BAL and blood CD4+and CD8+ T cells in non-LS patients. In addition, the
expression of PPARγ was found to be reduced in blood
CD4+ and CD8+ T cells in non-LS patients compared
to LS patients.
These finding are consistent with prior published results
of PPARα and PPARγ expression in other inflammatory
disorders. PPARα expression was reported to be reduced
in the inflamed lung of LPS- or allergen-exposed mice.
Administration of fenofibrate (an PPARα agonist) in-
creased PPARα expression while decreasing the inflamma-
tory response [22]. Several studies showed that PPARα
expression is reduced in inflamed skin [23]. Additionally,
activation of PPARα with fenofibrate provides anti-
inflammatory activity in allergic asthma [24]. Klotz et al.,
Figure 6 Flow cytometric analysis of PPARs expression in peripheral blood CD4+ T cells. (a) PPARα. (b) PPARβ/δ. (c) PPARγ. HC (n = 6); LS
patients (n = 4); non-LS patients (n = 4). MFI: median fluorescence intensity. The boxes show median (25th-75th percentiles) values and the whiskers
show minimum and maximum values. Each symbol represents an individual patient.
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reduced in peripheral blood mononuclear cells (PBMCs) in
multiple sclerosis patients [25]. PPARγ expression is not-
ably decreased in the colon of patients with ulcerative col-
itis [26]. Furthermore, PPARγ is down-regulated in lung
tissue and epithelial cells of COPD patients [27].
Notably, PPARα and PPARγ ligand activation decreases
the expression of inflammatory cytokines, such as IFNγ
and TNFα by Th1 cells [10,11]. Previous studies from our
group showed decreased expression of Th1 cytokines
(INFγ and TNFα in BAL fluid cells in HLA-DR3+ sar-
coidosis patients (typically with Löfgren’s syndrome) as
compared with HLA-DR3− patients [28]. Consequently,
the reduced expression of PPARα in non-LS patients
could contribute to the more pronounced Th1 response
with elevated Th1 cytokines. The reduced expression of
PPARα in CD4+ and CD8+ T cells in non-LS patientscould contribute to a non-resolving disease and a worse
prognosis in these patients compared to patients with LS.
Interestingly, PPARα-deficient T regulatory cells
(Treg) lack suppressive capacity [29]. PPARα or PPARγ
deficient mice showed reduced Treg recruitment to the
sites of inflammation [30,29]. This could contribute to
the reduced quantity of Treg cells in BALF observed in
some studies [31,32] and the dysfunctional activity of
these cells in sarcoidosis patients [33].
Th17 cells have been implicated also in sarcoidosis,
although with conflicting results regarding their fre-
quency [32,34,35], but the majority of BALF Th17 cells
produce both IL-17 and INFγ (Th17 INFγ+) [32,36].
Th17 INFγ+ cells are thought to be pathogenic in several
autoimmune diseases [37]. The activation of PPARα or γ
reduces INFγ as well as IL-17 production in T cells
[38,39]. In addition, PPARγ activation in CD4+ T cells
Figure 7 Representative histogram overlay (a) of PPARα expression in alveolar macrophages and the gating of alveolar macrophages
in a FSC-SCC dot (b). Black histogram is the isotype control; light gray histogram is the anti-PPARα. The x-axis of each histograms represents
fluorescence intensity of the isotype and PPARα on a logarithmic scale, and the y-axis represents the total number of events. The values of the
medians using the x-axis channels are presented in the table.
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PPARα or PPARγ could be potential therapeutic targets
in sarcoidosis.
Our study shows that the expression of PPARα mRNA
is reduced in BAL CD4+ T cells in both LS and non-LS
patients, but the expression of PPARα protein in LS pa-
tients is to some degree higher or at least comparable
with the expression of PPARα protein in HC. This dis-
crepancy highlights the importance of analyzing PPARs
expression on both mRNA and protein level. RT-PCR
assesses mRNA levels, which may be subject to post
translational modifications that prevent subsequent pro-
tein production of functional proteins. In humans, the
correlation between mRNA and protein concentration is
very modest [41]. Our study utilizes flow cytometry to
investigate the intracellular PPARs-protein expression at
the level of an individual cell and the quantification of
PPARs-protein by evaluation of MFI [42].
The role and expression of PPARβ/δ in inflammatory
cells and in pulmonary disease is less well-established
[6]. We found that PPARβ/δ mRNA expression is higher
in total BAL cells in non-LS patients compared to LS
patients and HC, and a tendency towards higher PPARδ
protein expression in blood CD4+ and CD8+ T cells in
sarcoidosis patients. N al Yacoub et al., showed that
PPARδ is expressed both at mRNA and the protein level
in human T cells, and that INF-α but not TCR stimula-
tion causes increased expression of PPARδ mRNA in
peripheral human T cells [11]. Again, ligand activatedPPARδ repress the production of INFγ and IL-17 in T
cells [43].
The similar levels of PPARs expression in both CD4+
and CD8+ T cells in this study are not unique for these
transcription factors and have been documented for other
transcription factors such as p-STAT1 and p-STAT6 [44].
Our data show that PPARs mRNA and protein expres-
sion in AM is comparable with HC in sarcoidosis pa-
tients. In contrast to a previous finding [12] we could
not verify that PPARγ expression is reduced in whole
BAL cells or AM from patients with sarcoidosis. An ex-
planation for this difference could be clinical differences
in the study populations, since PPARγ gene expression
in BAL cells seems only to be reduced in patients with
severe and treatment requiring sarcoidosis [13]. This
may affect the T-cell driven inflammation, since deletion
of PPARγ in alveolar macrophages is associated with
Th1 pulmonary inflammatory response [45].
Our results suggest that the reduced expression of
PPARα and PPARγ contribute to the persistent T-cell
driven immunoresponse noted in non-resolving sarcoid-
osis, common in non-LS patients. The lower expression
of these transcription factors in T cells from non-LS pa-
tients is in agreement with our previous demonstration
of higher IFNγ expression in BAL T cells in that patient
group. It is worth mentioning that studies have not evi-
dently demonstrated that corticosteroids or any other
therapy prevents progression or fibrosis [46,47]. The role
of TNF-blocking agents in treating sarcoidosis is less
Figure 8 Flow cytometric analysis of PPARs expression in alveolar macrophages. (a) PPARα. (b) PPARβ/δ. (c) PPARγ. HC (n = 6); LS patients
(n = 4); non-LS patients (n = 5). MFI: median fluorescence intensity. The boxes show median (25th-75th percentiles) values and the whiskers show
minimum and maximum values. Each symbol represents an individual patient.
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resolve all aspects of the disease [15]. PPARs could be
possibly novel targets for regulating the inflammatory
processes in sarcoidosis, and continued research may re-
sult in an alternative approach to the treatment. Indeed,
a clinical trial showed that short-term treatment with
rosiglitazone (PPARγ agonist) is effective in patients with
mild to moderately active ulcerative colitis [48]. In
addition, an investigative clinical trial to explore the ef-
fect of rosiglitazone, has shown modest improvements
in lung function measurements in a group of smokers
with mild to moderate asthma [49]. Since fibrate drugs
such as gemfibrozil are ligands for PPARα, the reduced
expression of PPARα in T cells of sarcoidosis patients
without LS may suggest that this class of drugs may also
become candidate for treatment of sarcoidosis.Additional files
Additional file 1: Figure S1. Flow cytometric analysis of PPARs
expression in BAL CD3+ CD8+ T cells. (a) PPARα. (b) PPARβ/δ. (c) PPARγ.
HC (n = 6); LS patients (n =4); non-LS patients (n = 4). The boxes show
median (25th-75th percentiles) values and the whiskers show minimum
and maximum values. Each symbol represents an individual patient.
Additional file 2: Figure S2. Flow cytometric analysis of PPARs
expression in peripheral blood CD3+ CD8+ T cells. (a) PPARα. (b) PPARβ/δ. (c)
PPARγ. HC (n = 6); LS patients (n = 4); non-LS patients (n = 4). The boxes show
median (25th-75th percentiles) values and the whiskers show minimum and
maximum values. Each symbol represents an individual patient.
Additional file 3: Figure S3. Comparison of PPARα, PPARβ/δ and
PPARγ expression between BAL and blood CD4+ T cells in the same
individual. MFI: median fluorescence intensity. (*p <0.05, Wilcoxon’s
signed ranks test). HC (n = 6); LS patients (n = 4); non-LS patients (n = 4).
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